EMA Withdrawn: Topotecan Actavis (topotecan) — Actavis Group PTC ehf

View source ↗

Summary

EMA withdrawn topotecan (Topotecan Actavis) indicated for uterine cervical neoplasms and small cell lung carcinoma; product withdrawn by MAH Actavis Group PTC e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Carcinoma
• Uterine Cervical Neoplasms

Drugs mentioned

• Topotecan Actavis (topotecan)

Snippet

Status: Withdrawn. Therapeutic area: Uterine Cervical Neoplasms;Small Cell Lung Carcinoma. MAH: Actavis Group PTC ehf. Decision date: 15/01/2019